Alchemia preps for $60mn US IPO for oncology spin-off Audeo
This article was originally published in Scrip
Executive Summary
Audeo Oncology, the cancer drug spinoff from Australia's Alchemia, filed for an initial public offering in the US on 6 July in hopes of raising up to $60 million at an undisclosed price per share.